Roche, LumiraDx Deal Probed by U.K. Competition Watchdog
Provided by
Dow Jones
By Michael Susin
The U.K. Competition and Markets Authority said it launched a merger inquiry regarding whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care technology could hurt competition in the country.
The CMA said Friday that it has until July 19 to reach a phase one decision.
Both companies weren't immediately available for comments.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
May 24, 2024 02:26 ET (06:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase